Form 4: Corbus Pharmaceuticals CFO Sean Moran Reports Stock and Option Awards

Sean Moran, CFO of Corbus Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Summary

• On January 31, 2025, Sean Moran, the CFO of Corbus Pharmaceuticals, reported changes in beneficial ownership to the SEC.
• Moran was granted 27,500 restricted stock units (RSUs) that will be settled in shares of common stock.
• These RSUs vest 25% annually, starting on January 31, 2026.
• The vesting of RSUs may accelerate pro rata upon termination of service by the company without cause after the first vesting date.
• Moran also acquired stock options for 92,500 shares with an exercise price of $9.79, which expire on January 31, 2035.
• 25% of these options vest on January 31, 2026, and the remaining 75% vest monthly over 36 months starting February 28, 2026.
• Following these transactions, Moran beneficially owns 76,105 shares of common stock, including 67,676 unvested RSUs.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options incentivize long-term performance and retention.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the equity awards.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives. The specific terms of these grants are typical for aligning management interests with shareholder value.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options and RSUs to incentivize their executives.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates